Our Pricing

How Long Does Wegovy Stay In Your System? Available Now

Published on: June 03, 2026

Understanding how long does Wegovy stay in your system UK is essential for patients considering treatment breaks, managing side effects, or planning medical procedures. Wegovy (semaglutide) has a half-life of approximately 7 days, meaning it takes around 5-7 weeks for the medication to be fully eliminated from your body after your final injection [1]. At Cured Pharmacy, our UK-registered clinical team provides comprehensive support throughout your weight loss journey, including guidance on treatment management and discontinuation.

Wegovy Half-Life and Elimination Timeline

Semaglutide, the active ingredient in Wegovy, has a median half-life of approximately 7 days in clinical studies [1]. This extended half-life is what allows for once-weekly dosing, unlike earlier GLP-1 receptor agonists that required daily injections. The half-life refers to the time it takes for half of the medication to be eliminated from your bloodstream.

Based on pharmacokinetic principles, it typically takes 4-5 half-lives for a medication to be considered fully eliminated from the body [2]. For Wegovy, this translates to approximately 5-7 weeks after your last injection. However, individual elimination times may vary based on factors including age, kidney function, liver function, and body composition.

During the elimination period, Wegovy's effects on appetite suppression and blood glucose regulation gradually diminish. Most patients notice increased appetite returning within 2-3 weeks after stopping treatment, though the medication remains detectable in the system for several more weeks [1].

Factors Affecting How Long Wegovy Stays in Your System

Several physiological factors influence semaglutide elimination rates. Patients with reduced kidney function may experience slightly prolonged elimination times, though clinical studies show no significant dose adjustment is required for mild to moderate renal impairment [3]. Similarly, hepatic impairment does not substantially alter semaglutide pharmacokinetics, as the medication is primarily degraded through proteolytic cleavage rather than liver metabolism.

Your maintenance dose also affects total drug exposure. Patients on the maximum 2.4mg weekly dose will have higher steady-state concentrations than those on lower doses, though the elimination half-life remains consistent across dose ranges [1]. Body weight and composition play a minor role, with steady-state concentrations reached after approximately 4-5 weeks of consistent weekly dosing.

Age and Metabolic Considerations

Clinical trials demonstrated no clinically significant differences in semaglutide pharmacokinetics based on age alone [3]. However, older patients with multiple comorbidities or reduced organ function may experience marginally extended elimination periods. Your UK prescriber will consider these individual factors when recommending treatment plans and monitoring schedules.

What Happens When You Stop Taking Wegovy

Discontinuing Wegovy does not cause acute withdrawal symptoms, as GLP-1 receptor agonists do not create physical dependence [4]. However, patients typically experience a gradual return of appetite and previous eating patterns as semaglutide levels decline. The STEP clinical trial extension studies showed that patients who discontinued semaglutide regained approximately two-thirds of their lost weight within one year of stopping treatment [5].

Common experiences after stopping Wegovy include increased hunger signals within 2-3 weeks, changes in satiety perception, and potential return of food cravings that were previously suppressed. Blood glucose levels in patients without diabetes typically return to baseline without adverse effects, though those with type 2 diabetes may require alternative glycaemic management [4].

Some patients report temporary gastrointestinal changes during the washout period as the digestive system readjusts to normal gastric emptying rates. These are generally mild and resolve within 3-4 weeks as semaglutide is eliminated.

Restarting Treatment After a Break

If you need to restart Wegovy after a break longer than 2 weeks, UK prescribing guidelines typically recommend returning to the initial 0.25mg dose and following the standard titration schedule [1]. This approach minimises gastrointestinal side effects and allows your body to readjust to the medication. Your prescriber at Cured Pharmacy will assess your individual circumstances and determine the most appropriate restart protocol.

How Long Does Wegovy Stay in Your System for Medical Procedures

Patients scheduled for surgical procedures or endoscopic examinations should inform their healthcare team about Wegovy use, as GLP-1 receptor agonists slow gastric emptying and may increase aspiration risk under anaesthesia [6]. Current UK anaesthetic guidance suggests considering temporary discontinuation of GLP-1 medications before elective procedures, though specific timing recommendations vary by institution.

The extended half-life of semaglutide means that gastric emptying effects may persist for 3-5 weeks after the last dose, even as blood levels decline [6]. Some anaesthetists recommend stopping Wegovy 4-6 weeks before major elective surgery to ensure complete gastric normalisation, whilst others assess risk individually based on procedure type and patient factors.

For emergency procedures, anaesthetic teams will implement appropriate aspiration precautions regardless of when you last injected Wegovy. Always inform medical professionals about your current and recent medication use, including the date of your last Wegovy injection.

Wegovy Detection and Drug Testing

Semaglutide is not a controlled substance and is not included in standard drug screening panels used by employers or sports organisations. However, the medication is detectable through specific laboratory assays if required for clinical monitoring purposes. Therapeutic drug monitoring for semaglutide is not routinely performed in clinical practice, as dosing is standardised rather than adjusted based on blood levels.

For patients concerned about medication disclosure for insurance or occupational health purposes, Wegovy is a legitimate prescription medication licensed by the MHRA for weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. All prescriptions issued through Cured Pharmacy are documented in your clinical record and can be verified if needed.

Pregnancy and Wegovy Elimination

Women planning pregnancy should discontinue Wegovy at least 2 months before attempting conception, allowing for complete elimination of semaglutide from the system [1]. This precautionary measure ensures no foetal exposure during critical early developmental stages. Your UK prescriber will provide comprehensive preconception counselling if pregnancy is planned during or after Wegovy treatment.

Alternative Weight Loss Treatments at Cured Pharmacy

If Wegovy's extended system retention is a concern for your circumstances, alternative weight management options are available through Cured Pharmacy. Mounjaro (tirzepatide) offers dual GIP/GLP-1 receptor agonism with superior weight loss outcomes in clinical trials, achieving average reductions of 22.5% body weight over 72 weeks in the SURPASS-3 study [7]. Tirzepatide has a similar half-life to semaglutide, with once-weekly dosing and comparable elimination timelines.

Saxenda (liraglutide) represents a daily injection alternative with a much shorter half-life of approximately 13 hours, allowing for more rapid elimination if treatment needs to be stopped quickly [8]. Complete clearance occurs within 2-3 days of the last injection, making it suitable for patients who require greater dosing flexibility or have upcoming medical procedures.

For patients preferring non-injectable options, Orlistat and Mysimba offer oral alternatives with different mechanisms of action and elimination profiles. All prescription weight loss treatments available at Cured Pharmacy require clinical assessment by a UK-registered prescriber, with prices displayed transparently before consultation. Our team ensures you receive the most appropriate treatment for your individual medical needs and circumstances.

Scientific References

1. Novo Nordisk. (2023). Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Teare, J. P., & Greenfield, S. M. (2022). Principles of clinical pharmacology and therapeutics. In Kumar & Clark's Clinical Medicine (10th ed., pp. 23-45). Elsevier. [accessed 13 August 2026]
3. Kalra, S., Baruah, M. P., & Sahay, R. (2021). Semaglutide in clinical practice: Dosing, administration and practical guidance. Diabetes Therapy, 12(7), 1921-1932. https://doi.org/10.1007/s13300-021-01087-0 [accessed 13 August 2026]
4. Rubino, D., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. Wilding, J. P. H., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. https://doi.org/10.1111/dom.14725 [accessed 13 August 2026]
6. American Society of Anesthesiologists. (2023). Consensus-based guidance on preoperative management of patients on glucagon-like peptide-1 (GLP-1) receptor agonists. ASA Practice Parameters. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance [accessed 13 August 2026]
7. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
8. Pi-Sunyer, X., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.